Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Blood proteins or globulins – e.g. – proteoglycans – platelet...
Reexamination Certificate
2002-06-05
2008-11-25
Belyavskyi, Michail (Department: 1644)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Blood proteins or globulins, e.g., proteoglycans, platelet...
C530S387300
Reexamination Certificate
active
07456263
ABSTRACT:
The invention provides T-cell receptor (TCR) molecules comprising a Vα chain and a Vβ chain that bind peptides derived from the p53 protein, preferably, the human p53 protein. The TCR molecules include both heterodimeric molecules and single chain molecules which specifically bind a sequence preferably spanning about amino acid positions 264-272 of the p53 protein displayed in the context of an HLA molecule, preferably, HLA-A2.1. Also disclosed are methods for making and using such TCR molecules. The invention has a wide spectrum of useful application including therapeutic uses and use in the detection of cells expressing p53 protein.
REFERENCES:
patent: 4867973 (1989-09-01), Goers et al.
patent: 5057313 (1991-10-01), Shih et al.
patent: 5106955 (1992-04-01), Endo et al.
patent: 5164311 (1992-11-01), Gupta
patent: 5830755 (1998-11-01), Nishimura et al.
patent: 5990275 (1999-11-01), Whitlow et al.
patent: 6015556 (2000-01-01), Bagshawe
patent: 6399368 (2002-06-01), Ward
patent: 6623957 (2003-09-01), Ward
patent: WO 93/24525 (1993-12-01), None
patent: WO 96/18409 (1996-06-01), None
patent: WO 00/23087 (2000-04-01), None
Mikayama et al. Molecular cloning and functional expression of a cDNA encoding glycosylation -inhibiting factor. PNAS, 1993. 90: 10056-10060.
Lazar et al. Transforming growth factor alpha: Mutation of aspartic acid 47 and leucine 48 results in different biological activities. Mol. Cell. Biol. 1988; 8: 1247-1252.
Skolnick et al. From genes to protein structure and function: novel applications of computational approaches in the genomic era. Trends in Biotech. 2000; 18(1): 34-39.
Rudikoff et al. Single amino acid substitution altering antigen-binding specificity. Proc. Natl. Acad. Sci. 1982; 79: 1979-1983.
Panka et. al. Variable region framework differences result in decreased or increased affinity of variant anti-digoxin antibodies. Proc. Natl. Acad. Sci. 1988; 85: 3080-3083.
Theobald et.al. Targeting p53 as a general tumor antigen. PNAS. 1995; 92: 11993-11997.
Chung et.al. Functional three-domain single-chain T-cell receptors. PNAS. 1994; 91: 12654-12658.
MSN Encarta Dictionary. p. 1-2.
Carding et al., Nat Rev Immunol. May 2002;2(5):336-45, in particular p. 338.
Sykulev et al., Proc Natl Acad Sci U S A. Nov. 22, 1994;91(24):11487-91.
Janeway et al., Immunobiology, 5th Ed., Garland Science, pp. 105-108 (2001).
Chien et al., Proc Natl Acad Sci U S A. Jul. 1989;86(14):5532-6.
Vajdos et al., J Mol Biol. Jul. 5, 2002;320(2):415-28.
Colman P. M., Research in Immunology, 145:33-36, 1994.
Liu, et al., “Targeting of Human p53-overexpressing Tumor Cells by an HLA A*0201-restricted Murine T-Cell Receptor Expressed in Jurkat T Cells1”, Cancer Research 60, 693-701, Feb. 1, 2000.
Weidanz J. A. et al. “Display of Functional Alphabeta Single-Chain T-Cell Receptor Molecules On The Surface of Bacteriophage”, Journal of Immunological Methods, Elsevier Science Publishers B.V., Amsterdam, NL, vol. 221, No. 1-2, Dec. 1998, pp. 59-76.
Theobald M. et al. “Targeting p53 As A General Tumor Antigen”, Proceedings Of The National Academy of Sciences Of USA, National Academy Of Science, Washington, DC, US, vol. 92, Dec. 1995, pp. 11993-11997.
Hoffman, T. K. et al. “Generation Of T Cells Specific For The Wild-Type Sequence p53(264-272) Peptide In Cancer Patients: Implications For Immunoselection Of Epitope Loss Variants”, Journal Of Immunology (Baltimore, MD.: 1950) Nov. 15, 2000, vol. 165, No. 10, pp. 5938-5944.
Theobald, M. et al. “The Sequence Alteration Associated With A Mutational Hotspot In p53Protects Cells From Lysis By Cytotoxic T Lymphocytes Specific For A Flanking Peptide Epitope”, Journal Of Experimental Medicine, Tokyo, JP, vol. 188, No. 6, Sep. 21, 1998, pp. 1017-1028.
Gnjatic S. et al. “Mapping And Ranking Of Potential Cytotoxic T Epitopes In The p53 Protein: Effect Of Mutations And Polymorphism On Peptide Binding Topurified And Refolded HLA Molecules”, European Journal Of Immunology, Weinheim, DE, vol. 25, Jun. 1, 1995, pp. 1638-1642.
Theobald, M. et al. “Tolerance To p53 By A2.1-Restricted Cytotoxic T Lymphocytes”, Journal Of Experimental Medicine, Tokyo, JP, vol. 185, No. 5, 1997, pp. 833-841.
Card, Kimberllyn F. et al. A Soluble Single-Chain T-Cell Receptor IL-2 Fusion Protein Retains.
Kuball, Juergen et al. “Cooperation Of Human Tumor-Reactive CD4+ And CD8+ T Cells After Redirection Of Their Specificity By A High-Affinity P53A2.1-Specific TCR”, Immunity, vol. 22, No. 1, Jan. 2005, pp. 117-129.
Card Kimberlyn F.
Sherman Linda A.
Thomson Elizabeth L.
Weidanz Jon A.
Wong Hing C.
Altor BioScience Corporation
Belyavskyi Michail
Corless Peter F.
Edwards Angell Palmer & & Dodge LLP
Skelding Zachary
LandOfFree
P53 binding T cell receptor molecules does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with P53 binding T cell receptor molecules, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and P53 binding T cell receptor molecules will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4037353